Literature DB >> 21946778

Acute coronary syndromes: Antithrombotics in ACS--moving beyond unfractionated heparin.

Usman Baber, Roxana Mehran.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21946778     DOI： 10.1038/nrcardio.2011.153

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  10 in total

1.  A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.

Authors:  M Cohen; C Demers; E P Gurfinkel; A G Turpie; G J Fromell; S Goodman; A Langer; R M Califf; K A Fox; J Premmereur; F Bigonzi
Journal:  N Engl J Med       Date:  1997-08-14       Impact factor: 91.245

Review 2.  2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Frederick G Kushner; Mary Hand; Sidney C Smith; Spencer B King; Jeffrey L Anderson; Elliott M Antman; Steven R Bailey; Eric R Bates; James C Blankenship; Donald E Casey; Lee A Green; Judith S Hochman; Alice K Jacobs; Harlan M Krumholz; Douglass A Morrison; Joseph P Ornato; David L Pearle; Eric D Peterson; Michael A Sloan; Patrick L Whitlow; David O Williams
Journal:  J Am Coll Cardiol       Date:  2009-12-01       Impact factor: 24.094

3.  Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium.

Authors:  Roxana Mehran; Sunil V Rao; Deepak L Bhatt; C Michael Gibson; Adriano Caixeta; John Eikelboom; Sanjay Kaul; Stephen D Wiviott; Venu Menon; Eugenia Nikolsky; Victor Serebruany; Marco Valgimigli; Pascal Vranckx; David Taggart; Joseph F Sabik; Donald E Cutlip; Mitchell W Krucoff; E Magnus Ohman; Philippe Gabriel Steg; Harvey White
Journal:  Circulation       Date:  2011-06-14       Impact factor: 29.690

4.  ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction).

Authors:  T J Ryan; J L Anderson; E M Antman; B A Braniff; N H Brooks; R M Califf; L D Hillis; L F Hiratzka; E Rapaport; B J Riegel; R O Russell; E E Smith; W D Weaver
Journal:  J Am Coll Cardiol       Date:  1996-11-01       Impact factor: 24.094

5.  Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial.

Authors:  Gilles Montalescot; Uwe Zeymer; Johanne Silvain; Bertrand Boulanger; Marc Cohen; Patrick Goldstein; Patrick Ecollan; Xavier Combes; Kurt Huber; Charles Pollack; Jean-François Bénezet; Olivier Stibbe; Emmanuelle Filippi; Emmanuel Teiger; Guillaume Cayla; Simon Elhadad; Frédéric Adnet; Tahar Chouihed; Sébastien Gallula; Agnès Greffet; Mounir Aout; Jean-Philippe Collet; Eric Vicaut
Journal:  Lancet       Date:  2011-08-20       Impact factor: 79.321

6.  Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.

Authors:  Gilles Montalescot; Harvey D White; Richard Gallo; Marc Cohen; P Gabriel Steg; Philip E G Aylward; Christoph Bode; Massimo Chiariello; Spencer B King; Robert A Harrington; Walter J Desmet; Carlos Macaya; Steven R Steinhubl
Journal:  N Engl J Med       Date:  2006-09-07       Impact factor: 91.245

7.  Use of anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction: a report from the NCDR ACTION Registry--GWTG (National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry--Get With the Guidelines).

Authors:  Mitul B Kadakia; Nihar R Desai; Karen P Alexander; Anita Y Chen; Joanne M Foody; Christopher P Cannon; Stephen D Wiviott; Benjamin M Scirica
Journal:  JACC Cardiovasc Interv       Date:  2010-11       Impact factor: 11.195

8.  Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.

Authors:  E M Antman; C H McCabe; E P Gurfinkel; A G Turpie; P J Bernink; D Salein; A Bayes De Luna; K Fox; J M Lablanche; D Radley; J Premmereur; E Braunwald
Journal:  Circulation       Date:  1999-10-12       Impact factor: 29.690

9.  Choice of arterial access site and outcomes in patients with acute coronary syndromes managed with an early invasive strategy: the ACUITY trial.

Authors:  Martial Hamon; Lars H Rasmussen; Steven V Manoukian; Angel Cequier; Michael A Lincoff; Hans-Jürgen Rupprecht; Bernard J Gersh; Tift Mann; Michel E Bertrand; Roxana Mehran; Gregg W Stone
Journal:  EuroIntervention       Date:  2009-05       Impact factor: 6.534

10.  A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes.

Authors:  Sunil V Rao; Kristi O'Grady; Karen S Pieper; Christopher B Granger; L Kristin Newby; Kenneth W Mahaffey; David J Moliterno; A Michael Lincoff; Paul W Armstrong; Frans Van de Werf; Robert M Califf; Robert A Harrington
Journal:  J Am Coll Cardiol       Date:  2006-01-26       Impact factor: 24.094
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.